Analyst Price Targets — PTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 4:29 pm | — | Stifel Nicolaus | $180.00 | $157.24 | TheFly | PTC price target lowered to $180 from $220 at Stifel |
| February 5, 2026 1:54 pm | — | RBC Capital | $195.00 | $155.99 | TheFly | PTC price target lowered to $195 from $235 at RBC Capital |
| February 5, 2026 12:42 pm | Daniel Jester | BMO Capital | $189.00 | $151.34 | TheFly | PTC price target lowered to $189 from $219 at BMO Capital |
| February 5, 2026 12:00 pm | — | KeyBanc | $210.00 | $151.34 | TheFly | PTC price target lowered to $210 from $245 at KeyBanc |
| January 28, 2026 12:36 pm | — | Oppenheimer | $200.00 | $164.63 | TheFly | PTC price target lowered to $200 from $240 at Oppenheimer |
| October 22, 2025 11:26 am | Joe Vruwink | Robert W. Baird | $255.00 | $204.55 | TheFly | PTC price target raised to $255 from $242 at Baird |
| July 31, 2025 10:45 am | — | KeyBanc | $245.00 | $202.51 | TheFly | PTC price target raised to $245 from $192 at KeyBanc |
| July 31, 2025 9:25 am | Saket Kalia | Barclays | $233.00 | $202.51 | TheFly | PTC price target raised to $233 from $203 at Barclays |
| July 29, 2025 3:23 pm | Kristen Kluska | Cantor Fitzgerald | $120.00 | $202.63 | Benzinga | These Analysts Increase Their Forecasts On PTC Therapeutics |
| May 1, 2025 11:01 am | Clarke Jeffries | Piper Sandler | $180.00 | $156.34 | TheFly | PTC price target lowered to $180 from $202 at Piper Sandler |
Latest News for PTC
BOSTON, Feb. 27, 2026 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: KeyBanc Capital Markets Emerging Technology Summit When: 1x1's on Tuesday, March 3, 2026 What: Morgan Stanley Technology, Media & Telecom Conference When: Wednesday, March 4, 2026 at 4:05pm PST What: BofA Securities 33rd Annual Industrials, Transportation & Airlines Key Leaders…
Introduces the only cloud-native MBD capability built into the core modeling experience, fully integrated within CAD and PDM Creates a single, always-up-to-date product definition by embedding manufacturing information directly in the live 3D model Improves collaboration and change control across engineering and manufacturing BOSTON, Feb. 26, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the release of a…
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and…
Aurora Investment Counsel decreased its position in PTC Inc. (NASDAQ: PTC) by 70.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,395 shares of the technology company's stock after selling 5,716 shares during the quarter. Aurora Investment Counsel's holdings in PTC
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.